ACIP Presentation Slides: September 29, 2021 Meeting

Note: These files are not yet 508

Slides will be added as they become available.

September 29, 2021

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Tick-borne Encephalitis (TBE) Vaccine

• Introduction; Immunogenicity and safety of TBE vaccine; Summary and next steps [56 pages]
  Dr. K Poehling; Dr. S Hills

Zoster Vaccines

• Introduction [10 pages]
  Dr. C Kotton
• Economics of vaccinating immunocompromised 19–49-year-old adults against herpes zoster in the US [17 pages]
  Dr. I Ortega-Sanchez
• Preliminary EtR regarding use of RZV in immunocompromised adults and next steps [79 pages]
  Dr. T Anderson

Pneumococcal Vaccines

• Introduction [17 pages]
  Dr. K Poehling
  
• Summary of economic models assessing pneumococcal vaccines in US adults [30 pages]
  Dr. A Leidner
• EtR on risk-based use of PCV15 and PCV20 in adults; Considerations for use of PCV15 and PCV20 in adults and next steps [101 pages]
  Dr. M Kobayashi

Hepatitis B Vaccines

• Introduction [4 pages]
  Dr. K Ault
  
• HepB-CpG postmarketing surveillance study [23 pages]
  Dr. K Bruxvoort
• Universal adult HepB: EtR [81 pages]
  Dr. M Doshani

Orthopoxviruses Vaccines

• Introduction [7 pages]
  Dr. P Sanchez
  
• Background information to interpret GRADE tables and Evidence to Recommendations frameworks about JYNNEOS® [25 pages]
  Dr. A Rao
• Evidence to Recommendations Frameworks for Use of JYNNEOS® [89 pages]
  Dr. A Rao